Reactive oxygen species (ROS) are mutagenic and may thereby promote cancer 1 . Normally, ROS levels are tightly controlled by an inducible antioxidant program that responds to cellular stressors and is predominantly regulated by the transcription factor Nrf2 (also known as Nfe2l2) and its repressor protein . In contrast to the acute physiological regulation of Nrf2, in neoplasia there is evidence for increased basal activation of Nrf2. Indeed, somatic mutations that disrupt the Nrf2-Keap1 interaction to stabilize Nrf2 and increase the constitutive transcription of Nrf2 target genes were recently identified, indicating that enhanced ROS detoxification and additional Nrf2 functions may in fact be protumorigenic 6 . Here, we investigated ROS metabolism in primary murine cells following the expression of endogenous oncogenic alleles of Kras, Braf and Myc, and found that ROS are actively suppressed by these oncogenes. K-Ras G12D , B-Raf V619E and Myc ERT2 each increased the transcription of Nrf2 to stably elevate the basal Nrf2 antioxidant program and thereby lower intracellular ROS and confer a more reduced intracellular environment. Oncogene-directed increased expression of Nrf2 is a new mechanism for the activation of the Nrf2 antioxidant program, and is evident in primary cells and tissues of mice expressing K-Ras G12D and B-Raf V619E , and in human pancreatic cancer. Furthermore, genetic targeting of the Nrf2 pathway impairs K-Ras G12D -induced proliferation and tumorigenesis in vivo. Thus, the Nrf2 antioxidant and cellular detoxification program represents a previously unappreciated mediator of oncogenesis.
Reactive oxygen species (ROS) are mutagenic and may thereby promote cancer 1 . Normally, ROS levels are tightly controlled by an inducible antioxidant program that responds to cellular stressors and is predominantly regulated by the transcription factor Nrf2 (also known as Nfe2l2) and its repressor protein Keap1 (refs 2-5) . In contrast to the acute physiological regulation of Nrf2, in neoplasia there is evidence for increased basal activation of Nrf2. Indeed, somatic mutations that disrupt the Nrf2-Keap1 interaction to stabilize Nrf2 and increase the constitutive transcription of Nrf2 target genes were recently identified, indicating that enhanced ROS detoxification and additional Nrf2 functions may in fact be protumorigenic 6 . Here, we investigated ROS metabolism in primary murine cells following the expression of endogenous oncogenic alleles of Kras, Braf and Myc, and found that ROS are actively suppressed by these oncogenes. K-Ras G12D , B-Raf V619E and Myc ERT2 each increased the transcription of Nrf2 to stably elevate the basal Nrf2 antioxidant program and thereby lower intracellular ROS and confer a more reduced intracellular environment. Oncogene-directed increased expression of Nrf2 is a new mechanism for the activation of the Nrf2 antioxidant program, and is evident in primary cells and tissues of mice expressing K-Ras G12D and B-Raf V619E , and in human pancreatic cancer. Furthermore, genetic targeting of the Nrf2 pathway impairs K-Ras G12D -induced proliferation and tumorigenesis in vivo. Thus, the Nrf2 antioxidant and cellular detoxification program represents a previously unappreciated mediator of oncogenesis.
To examine the role of ROS in cellular transformation and tumorigenesis, we used an endogenous and conditional oncogenic LSL-K-Ras G12D allele 7 . K-Ras G12D/1 and K-Ras LSL/1 mouse embryonic fibroblasts (MEFs) were compared to MEFs and NIH3T3 fibroblasts (NIH3T3s) transduced with K-Ras4B G12D and H-Ras V12 (Fig. 1a) , because ectopic Ras introduction was previously reported to increase ROS production 8 . In contrast to ectopic overexpression of oncogenic Ras, K-Ras G12D/1 MEFs demonstrated lower levels of hydrogen peroxide, superoxide and mitochondrial ROS compared to K-Ras LSL/1 MEFs ( Fig. 1a and Supplementary Fig. 2a, b) . Accordingly, the level of 7,8-dihydro-8-oxo-29-deoxyguanosine (8-oxo-dGuo), one of the major products of DNA oxidation, was decreased in MEFs expressing endogenous K-Ras G12D/1 , but increased by ectopic oncogenic Ras (Fig. 1b ). The levels of ROS and 8-oxo-dGuo were also lower in p53 2/2 ; K-Ras G12D/1 MEFs compared to p53 2/2 ; K-Ras LSL/1 MEFs (p53 is also known as Trp53; Supplementary Fig. 2c, d) , supporting that these differences are not due to differential activation of a senescence program and demonstrating that increased ROS production is not required for full transformation 7,9 . Because alterations of ROS can affect the intracellular redox state 10 , the ratio of reduced to oxidized glutathione (GSH/GSSG) was examined in cells expressing ectopic and endogenous K-Ras G12D elevated the level of total glutathione (Fig. 1d , f and ref. 11), only the endogenous expression of K-Ras G12D elevated the GSH/GSSG ratio to promote a more reduced intracellular environment ( Fig. 1c, e ). The production of ROS by ectopic oncogenic Ras is chiefly regulated by NADPH-oxidase (Nox) 12 . Only the ectopic overexpression of oncogenic Ras increased Nox activity and messenger RNA, providing a mechanistic explanation for these differing results ( Supplementary  Fig. 3 ). Similar to oncogenic Ras, ectopic expression of Myc has also been shown to increase the production of ROS in NIH3T3 fibroblasts 13 and accordingly we sought to determine whether near-physiological expression of this oncogene had a similar effect. Treatment of R26 MER/MER MEFs, which express a homozygous Myc ERT2 allele under the control of the Rosa26 promoter 14 , with 4-hydroxytamoxifen (4-OHT) resulted in a substantial reduction of ROS ( Fig. 1g ). However, this was not a characteristic feature of all oncogenic stimuli as expression of activated Notch1 and b-catenin did not lower ROS (Supplementary Fig. 4 ). Therefore, endogenous expression of oncogenic K-Ras or Myc ERT2 lowers the level of cellular ROS, in contrast to the ectopic overexpression of these oncogenes.
As the intracellular redox state is chiefly regulated by Nrf2, we examined Nrf2 protein levels and activity in K-Ras LSL/1 and K-Ras G12D/1 MEFs by western blot, reporter assay and chromatin immunoprecipitation (ChIP) analysis of the Nrf2 target genes Hmox1 and Nqo1. Expression of K-Ras G12D resulted in an approximately twofold increase in Nrf2 protein and binding activity compared to control MEFs ( Fig. 2a, b and Supplementary Fig. 5a ), which was not attributable to altered regulation by Keap1 (ref. 2 and Supplementary Fig. 6 ). K-Ras G12D/1 MEFs showed increased Nrf2 mRNA and increased expression of Hmox1, Nqo1, Gclc, Gclm and Ggt1 mRNA and protein ( Fig. 2c and Supplementary Fig. 5b ). Increased expression of Nrf2 and its target genes was also observed following K-Ras G12D expression in p53 2/2 MEFs, and following ectopic expression of K-Ras G12D and H-Ras V12 in primary MEFs, but not following expression of activated Notch1 or b-catenin ( Supplementary Fig. 5c -g). However, expression of K-Ras G12D in Nrf2-deficient MEFs failed to elevate total glutathione levels and resulted in a more oxidized intracellular environment ( Fig. 2d, e ). Neither the cell culture conditions employed to express K-Ras G12D nor the gene dosage of wild-type K-Ras affected the expression of Nrf2 target genes ( Supplementary  Fig. 7a, b ). Additionally, ROS metabolism in wild-type MEFs was sensitive to acute changes in the levels of Keap1 and Nrf2, further supporting a causal relationship between Nrf2 and ROS (Supplementary Fig. 7c-e ). Furthermore, acute knockdown of Nrf2 attenuated the reduction in ROS by K-Ras G12D (Fig. 2f ), and the effects of Nrf2 depletion on ROS were dosage-dependent, supporting the importance of the level of Nrf2 mRNA for ROS control ( Supplementary Fig. 7f , g). Similar to K-Ras G12D , activation of c-Myc ERT2 (with 4-OHT) promoted an increase in the mRNA and protein levels of Nrf2 and its target genes (Fig. 2g, h and Supplementary Fig. 7h ). Furthermore, ChIP-seq data from the ENCODE consortium demonstrated direct binding of Myc to the Nfe2l2 locus ( Supplementary Fig. 8a) 15 . Therefore, the K-Ras and Myc oncogenes can constitutively increase the transcription of Nrf2 to elevate the basal activity of the antioxidant and cellular detoxification program.
To investigate the mechanism of Nrf2 activation by K-Ras G12D , the roles of the Raf/MEK/ERK and p38alpha (also known as Araf/Braf/Raf1, Map2k1/2, Mapk1/2 and Mapk14) MAPK pathways were investigated. First, cells were treated with a potent and specific inhibitor of MEK, AZD6244 (ARRY-142886) ( Supplementary Fig. 9a -c), which restored the ROS level of K-Ras G12D/1 cells almost to the level of K-Ras LSL/1 cells ( Fig. 3a) . Additionally, AZD6244 treatment resulted in decreased induction of Nrf2 and its target genes (Fig. 3b ). Furthermore, endogenous expression of B-Raf V619E (corresponding to human B-Raf V600E ) 16 resulted in increased phospho-ERK levels, a decrease in ROS, and an increase in Nrf2 mRNA and antioxidant gene expression (Supplementary Fig. 9d-f ). As previously reported 17 , we found that p38alpha MAPK did not activate Nrf2 ( Supplementary Fig. 9g -i). To determine the mechanism of increased Nrf2 expression, transcription factors downstream of MAPK signalling were examined. Accordingly, knockdown of Jun, Fra1 (also known as Fosl1) and Myc, but not JunD or Elk1, 
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decreased the Nrf2 mRNA in K-Ras G12D/1 cells, with almost complete rescue achieved with Jun ( Fig. 3c ). Short interfering RNA (siRNA) efficiency was confirmed by real-time PCR and western blot (Supplementary Fig. 10a, b) . Importantly, K-Ras G12D/1 MEFs and B-Raf V619E MEFs showed elevated Jun protein levels compared to control MEFs, and the elevated Jun level in K-Ras G12D/1 MEFs was rescued by treatment with AZD6244 ( Fig. 3d ). Furthermore, depletion of Jun with siRNA prevented the decrease in ROS following expression of K-Ras G12D (Fig. 3e, Supplementary Fig. 10c ). Our results reinforce a prior finding that antioxidant response elements that closely resemble AP-1 sites help regulate the Nrf2 promoter 18 . Finally, ChIP-seq revealed that the transcriptional start site of the Nfe2l2 locus is a direct binding target of Jun ( Supplementary Fig. 8b ) 15 . Thus, K-Ras G12D and B-Raf V619E stimulate transcription of Nrf2 via Jun and Myc. We next examined whether these oncogenes promote activation of the Nrf2 antioxidant and cellular detoxification program in vivo. Elevated protein expression of the Nrf2 target gene Nqo1 and decreased immunoreactivity for 8-oxo-dGuo were evident in K-Ras mutant murine 19 and human pre-invasive pancreatic intraepithelial neoplasia (PanIN) and pancreatic ductal adenocarcinoma (PDA), and in murine lung adenomas expressing B-Raf V619E (Fig. 4a and Supplementary Figs 11a, 12, 13 and 14a ). PanIN also demonstrated reduced immunoreactivity for the lipid peroxidation adduct malondialdehyde (MDA) ( Supplementary Fig. 11b ). Furthermore, K-Ras G12D/1 pancreatic epithelial cells showed activation of Nrf2 and decreased ROS compared to K-Ras LSL/1 , whereas treatment of human PDA tumour lines with KRAS siRNA resulted in decreased Nrf2 and Nqo1 mRNA and an increase in ROS ( Supplementary Fig. 15 ). The activation of Nrf2 in human pancreatic cancer could not be explained by somatic mutations in NFE2L2 or KEAP1; we sequenced over 100 samples of human PDA and identified only one case with a concomitant KEAP1 and KRAS mutation ( Supplementary Information and Supplementary Fig. 14b ). Importantly, Nrf2-deficient murine PanIN were negative for Nqo1 and demonstrated similar levels of 8-oxo-dGuo and MDA in PanIN compared to neighbouring morphologically normal ductal cells, supporting a role for Nrf2 in ROS detoxification in vivo ( Fig. 4b and Supplementary  Fig. 11b, c) . Nrf2-deficient salivary gland did not demonstrate elevated 8-oxo-dGuo immunoreactivity, indicating that K-Ras G12D -expressing cells are more reliant on Nrf2 for ROS detoxification ( Supplementary  Fig. 16a ). Therefore, an antioxidant program is operant during tumorigenesis, consistent with our findings that link oncogenic K-Ras and B-Raf expression with the activation of Nrf2.
To investigate whether activation of Nrf2 promotes K-Ras G12Dinitiated carcinomas, the effects of Nrf2 ablation were examined in established mouse models of pancreatic and lung cancer. Nrf2deficient pancreata were noted to contain fewer PanIN (Fig. 4c ). Whereas the proliferation of the salivary gland was unchanged (Supplementary Fig. 16b ), PanIN from Nrf2-deficient mice were significantly less proliferative and demonstrated an increased content of cells showing senescence-associated b-galactosidase activity ( Fig. 4d and Supplementary Fig. 17a ). No significant differences were observed in PanIN cell apoptosis or DNA damage ( Supplementary Fig. 17b, c) . Senescence was also observed in K-Ras G12D/1 MEFs following acute depletion of Nrf2 with siRNA and was dependent on expression of p53 ( Supplementary Fig. 17d ). The Nrf2-dependent proliferation defect noted in PanIN was also observed in MEFs, and both could be rescued by the antioxidant N-acetyl cysteine ( Supplementary Fig. 18a, b ). Furthermore, treatment of Nrf2 1/1 PanIN mice with a glutathione synthesis inhibitor resulted in a significant decrease in the proliferation of PanIN but not adjacent acinar cells ( Supplementary Fig. 18c-e ). Additionally, the role of Nrf2 in lung cancer development was investigated. Nrf2 deficiency resulted in a significant reduction in disease burden and proliferation, and an increase in median survival ( Supplementary Fig. 19 ). Although we cannot exclude the potential involvement of non-cell-autonomous effects arising from constitutive Nrf2 deficiency, the major impact seemed to be restricted to tumour initiation and proliferation of nascent preneoplastic cells. These results demonstrate that Nrf2 promotes K-Ras G12D -initiated pancreatic and lung tumorigenesis and proliferation. 
RESEARCH LETTER
ROS can stimulate tumorigenesis through the oxidation of DNA and subsequent mutation of genes that promote carcinogenesis. In contrast, we found that activating a ROS-detoxification program contributed to tumorigenesis, although our study does not exclude a role for other Nrf2 targets such as drug-metabolizing enzymes and efflux pumps, heat shock proteins, 26S proteasome subunits, growth factors and receptors 6 . Future studies will be necessary to determine the role of these Nrf2 functions in tumours with activated Nrf2. Increased expression of Nrf2 target genes and increased stability of Nrf2 caused by somatic mutations in Nrf2 and Keap1 are well documented in human cancer, providing one mechanism for enhanced Nrf2 activity during tumorigenesis. Our work describes oncogenic signalling as an alternative mechanism to activate Nrf2 transcription during tumorigenesis ( Supplementary Fig. 1 ), and suggests that modulation of the redox state is uniformly important in cancer and may therefore represent a therapeutic opportunity. Thus, constitutively elevated Nrf2 activity in cancer cells occurs through two distinct mechanisms: diminished Nrf2 turnover and augmented Nrf2 mRNA levels.
METHODS SUMMARY
Mouse strains were described previously [20] [21] [22] , and were interbred onto the same genetic background (mixed B6/129/SJL) for tumour studies. Mice were infected intranasally with 10 7 plaque-forming units of adenoviral-cre as described 20 . Mice were maintained in compliance with UK Home Office regulations. Mouse embryonic fibroblasts were isolated from embryonic day 13.5 (E13.5) embryos, maintained in DMEM with 10% FCS and were plated at 70% confluence the day before use unless otherwise stated. Early-passage MEFs (passage 3-4) were used for all experiments, and at least three lines were examined for all studies. R26 MER/MER (G. Evan), R26-LSL-NIC (C. Murtaugh), APC fl/fl (O. Sansom), p38a 2/2 ; LSL-K-Ras G12D (J.-J. Ventura), and Jun 2/2 (E. Wagner) MEFs were generously provided. Adenoviral and retroviral transductions were performed as described 7 . NIH3T3 fibroblasts were obtained from the ATCC and maintained in DMEM with 10% FCS. For ROS measurements, cells were labelled in serum-and phenol-red-free media containing 5 mM dihydroethidium or 10 mM 29,79-dichlorofluorescein diacetate (both Sigma Aldrich) for 30 min, and analysed by flow cytometry. 8-oxo-dGuo and glutathione were measured by liquid chromatography-mass spectrometry as described 23, 24 . Protein lysates were prepared using 1% SDS lysis buffer and separated on 4-12% NuPAGE gels (Invitrogen), transferred onto a PVDF membrane (Millipore) and incubated with the following antibodies: actin (I-19), Keap1 (E-20), Nqo1 (C-19), Ggt1 (3E6) and B-Raf (F-7) (all Santa Cruz Biotechnologies); ERK, phospho-ERK (Thr202/Tyr204), Akt, phospho-AKT (S473), Jun and Elk1 (all Cell Signaling); Hmox1 (Stressgen) and b-catenin (BD Biosciences) were also used. Nrf2 western blots are described in the supplementary methods. RNA was isolated using an RNeasy kit (Qiagen). cDNA was synthesized using a High Capacity RNA to cDNA Master Mix and analysed by quantitative PCR (q-PCR) using TaqMan gene expression assays on a 7900HT Real-Time PCR system (all Applied Biosystems). Target gene expression was normalized to actin expression, and shown relative to control samples.
METHODS
Mouse strains and MEFs. Mouse strains were described previously [20] [21] [22] , and were interbred onto the same genetic background (mixed B6/129/SJL) for tumour studies. Mice were infected intranasally with 10 7 plaque-forming units of adenoviral-cre as described 20 . Mice were maintained in compliance with UK Home Office regulations. Mouse embryonic fibroblasts were isolated from embryonic day 13.5 (E13.5) embryos, maintained in DMEM with 10% FCS and were plated at 70% confluence the day before use unless otherwise stated. Early-passage MEFs (passage 3-4) were used for all experiments, and at least three lines were examined for all studies. R26 MER/MER (G. Evan), R26-LSL-NIC (C. Murtaugh), APC fl/fl (O. Sansom), p38a 2/2 ; LSL-K-Ras G12D (J.-J. Ventura) and Jun 2/2 (E. Wagner) MEFs were provided. Adenoviral and retroviral transductions were performed as described 7 . NIH3T3 fibroblasts were obtained from the ATCC and maintained in DMEM with 10% FCS. Analysis of 8-oxo-dGuo and glutathione. 8-oxo-dGuo and glutathione were measured by liquid chromatography-mass spectrometry as described 23, 24 . Chromatin immunoprecipitation. Chromatin immunoprecipitation was performed as described 25 . Cells (5 3 10 6 ) were fixed at 37 uC in DMEM with 1% formaldehyde for 10 min and lysed in 1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.1 plus protease inhibitors and sonicated for 20 min in a cold water bath until DNA was an average size of 1 kilobase. Input was saved and lysate was diluted in immunoprecipitation buffer (1% Triton, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl pH 8.1) and mixed with beads (Dynal Protein A, Invitrogen) that were pre-bound overnight with Nrf2 antibody (H-300, Santa Cruz). Chromatin was immunoprecipitated overnight, and beads were washed six times with RIPA buffer (50 mM HEPES pH 7.6, 1 mM EDTA, 0.7% Na deoxycholate, 1% NP-40, 0.5 M LiCl) and twice with TE. Beads were incubated with 1% SDS, 0.1 M NaHCO 3 for 30 min at room temperature, and then crosslinks were reversed on both the input and the immunoprecipitate by heating overnight in a 65 uC water bath. DNA was purified with a QIAquick spin kit (Qiagen) and Q-PCR was performed in triplicate with a Power SYBR Master Mix (Applied Biosystems) on an Applied Biosystems
